View in EDS

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Saved in:
Bibliographic Details
Title: Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Authors: Modi S., Jacot W., Yamashita T., Sohn J., Vidal M., Tokunaga E., Tsurutani J., Ueno N. T., Prat A., Chae Y. S., Lee K. S., Niikura N., Park Y. H., Xu B., Wang X., Gil-Gil M., Li W., Pierga J. -Y., Im S. -A., Moore H. C. F., Rugo H. S., Yerushalmi R., Zagouri F., Gombos A., Kim S. -B., Liu Q., Luo T., Saura C., Schmid P., Sun T., Gambhire D., Yung L., Wang Y., Singh J., Vitazka P., Meinhardt G., Harbeck N., Cameron D. A., nella lista degli sperimentatori, De Laurentiis M
Contributors: Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Maria Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil-Gil, Wei Li, Jean-Yves Pierga, Seock-Ah Im, Halle C F Moore, Hope S Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung-Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David A Cameron, DESTINY-Breast04 Trial Investigators, Sohn, Joo Hyuk
Source: Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Dipòsit Digital de la UB
instname
Modi, S, Jacot, W, Yamashita, T, Sohn, J, Vidal, M, Tokunaga, E, Tsurutani, J, T. Ueno, N, Prat, A, Chae, Y S, Seok Lee, K, Niikura, N, Hee Park, Y, Xu, B, Wang, X, Gil-Gil, M, Li, W, Pierga, J-Y, Im, S-A, C.F. Moore, H, S. Rugo, H, Yerushalmi, R, Zagouri, F, Gombos, A, Kim, S-B, Liu, Q, Luo, T, Saura, C, Schmid, P, Sun, T, Gambhire, D, Young, L, Wang, Y, Singh, J, Vitazka, P, Meinhardt, G, Harbeck, N & Cameron, D A 2022, ' Trastuzumab deruxtecan in previously treated HER2low advanced breast cancer ', New England Journal of Medicine . https://doi.org/DOI: 10.1056/NEJMoa2203690
Publisher Information: Massachusetts Medical Society, 2022.
Publication Year: 2022
Subject Terms: Immunoconjugates, Breast Neoplasms* / secondary, Receptor, ErbB-2, Humanized / adverse effects, ErbB-2* / genetics, Antineoplastic Agents, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Antibodies, Càncer de mama, Immunological* / therapeutic use, 03 medical and health sciences, Breast cancer, Antineoplastic Agents, Immunological, 0302 clinical medicine, Immunological* / adverse effects, Monoclonal, Humanized / therapeutic use, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms* / genetics, Camptothecin / analogs & derivatives, Humans, ErbB-2* / analysis, Breast Neoplasms* / metabolism, Trastuzumab* / adverse effects, 2. Zero hunger, Trastuzumab* / therapeutic use, Immunoconjugates / adverse effects, Sciences bio-médicales et agricoles, Trastuzumab, 16. Peace & justice, Immunohistochemistry, Immunoconjugates / therapeutic use, ErbB-2* / biosynthesis, 3. Good health, Disease Progression, Monoclonal antibodies, Camptothecin, Female, Anticossos monoclonals, Breast Neoplasms* / drug therapy, Receptor
Description: Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.We conducted a phase 3 trial involving patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy. (Low expression of HER2 was defined as a score of 1+ on immunohistochemical [IHC] analysis or as an IHC score of 2+ and negative results on in situ hybridization.) Patients were randomly assigned in a 2:1 ratio to receive trastuzumab deruxtecan or the physician's choice of chemotherapy. The primary end point was progression-free survival in the hormone receptor-positive cohort. The key secondary end points were progression-free survival among all patients and overall survival in the hormone receptor-positive cohort and among all patients.Of 557 patients who underwent randomization, 494 (88.7%) had hormone receptor-positive disease and 63 (11.3%) had hormone receptor-negative disease. In the hormone receptor-positive cohort, the median progression-free survival was 10.1 months in the trastuzumab deruxtecan group and 5.4 months in the physician's choice group (hazard ratio for disease progression or death, 0.51; P
Document Type: Article
File Description: application/pdf; No full-text files
Language: English
ISSN: 1533-4406
0028-4793
DOI: 10.1056/nejmoa2203690
Access URL: https://pubmed.ncbi.nlm.nih.gov/35665782
https://hdl.handle.net/2445/197309
https://hdl.handle.net/11588/963508
https://www.pure.ed.ac.uk/ws/files/279758838/nejmoa2203690.pdf
https://hdl.handle.net/20.500.11820/4095995e-3067-46c9-875a-a70cdb641427
https://hdl.handle.net/11588/963508
https://doi.org/10.1056/NEJMoa2203690
http://hdl.handle.net/2445/197309
Rights: CC BY NC ND
URL: http://www.nejmgroup.org/legal/terms-of-use.htm
Accession Number: edsair.doi.dedup.....6faab06c02bdc6f1099b2949ecd1867a
Database: OpenAIRE
Description
Abstract:Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.We conducted a phase 3 trial involving patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy. (Low expression of HER2 was defined as a score of 1+ on immunohistochemical [IHC] analysis or as an IHC score of 2+ and negative results on in situ hybridization.) Patients were randomly assigned in a 2:1 ratio to receive trastuzumab deruxtecan or the physician's choice of chemotherapy. The primary end point was progression-free survival in the hormone receptor-positive cohort. The key secondary end points were progression-free survival among all patients and overall survival in the hormone receptor-positive cohort and among all patients.Of 557 patients who underwent randomization, 494 (88.7%) had hormone receptor-positive disease and 63 (11.3%) had hormone receptor-negative disease. In the hormone receptor-positive cohort, the median progression-free survival was 10.1 months in the trastuzumab deruxtecan group and 5.4 months in the physician's choice group (hazard ratio for disease progression or death, 0.51; P
ISSN:15334406
00284793
DOI:10.1056/nejmoa2203690